HIV/AIDS
Findings from Harvard University Advance Knowledge in HIV/AIDS
Published in AIDS Weekly, April 16th, 2012
2012 APR 16 -- According to the authors of a study from Boston, Massachusetts, "Antiretroviral drugs have been recommended for post-exposure prophylaxis (PEP) after high-risk sexual exposures for more than a decade. Three drug regimens could offer the highest levels of protection, particularly if the infectious source is taking medication, but drug intolerance has often led to suboptimal adherence."
"The current study evaluated a novel 3-drug PEP regimen, consisting of raltegravir, tenofovir DF, and emtricitabine. Of 100 participants enrolled in this study at a Boston community health center that has had a comprehensive PEP program for more than a decade,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2012-04-16)
More Articles from AIDS Weekly
- HIV/AIDS
Investigators at Drexel University Detail Research in HIV/AIDS - HIV/AIDS
Data on HIV/AIDS Described by Researchers at School of Public Health - Antiretrovirals
Data on Antiretrovirals Reported by Researchers at Makerere University - Toxoplasmosis
Data from Center for Disease Control and Prevention Provide New Insights into Toxoplasmosis - HIV/AIDS
Studies from K.C. Takarinda et al in the Area of HIV/AIDS Described - HIV/AIDS
Research from University of Buenos Aires School of Medicine Provides New Data about HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
